United States
Germany
Japan
United Kingdom
China
AAV2 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
Others
AAV2 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV9-CMV-GFP Control Particle, 1 x 100 uL
AAV8-CMV-GFP Control Particle, 1 x 100 uL
AAV5 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV-PHP.eB with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV8 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV9 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAVDJ with CMV promoter-driven expression of GFP, >10^13 GC/mL, 1 x 100 uL
AAV1 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV5 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAVrh.10 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV6 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV3 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
AAV7 with CMV promoter-driven expression of GFP, >10^13 GC/mL, 50 ul
